SMARCA2 and cancer: PFI-3 is a selective, potent, and cell-permeable SMARCA2/4 bromodomain inhibitor that has been previously characterized in the setting of various cancers (e.g., lung cancer, synovial sarcoma, leukemia, and rhabdoid tumors) (66).